Haystack Oncology, a Quest Diagnostics (DGX) company, has entered into a collaboration with Alliance Foundation Trials for research use of Haystack Oncology’s personalized MRD technology (Haystack MRD(TM)) to analyze therapeutic response and provide molecular insights for AFT’s interventional, randomized phase II clinical trial (AFT-57) in patients with unresectable stage III non-small cell lung cancer. The AFT-57 clinical study is supported by Genentech, a member of the Roche Group (RHHBY), and will explore the efficacy and safety of an anti-PD-L1 atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DGX:
- Quest Diagnostics initiated with an Equal Weight at Barclays
- Quest Diagnostics price target raised to $150 from $145 at Truist
- Quest Diagnostics names Yuri A. Fesko, M.D., as Chief Medical Officer
- Quest Diagnostics management to meet with Truist
- Quest Diagnostics price target raised by $4 at JPMorgan, here’s why
